When we examined the impact of IL22 on prognosis after allogeneic SCT, including patients with and without GvHD, we observed significantly lower IL22 expression in the TRM group compared to the non-TRM group (p = 0.010, Figure 2A). This evidence concerns the gene IL22 and graft versus host disease.